PTC Therapeutics

What PTC Therapeutics does

PTC Therapeutics is a global biopharmaceutical company founded in 1998 and headquartered in Warren, New Jersey (with international headquarters in Dublin, Ireland). The company discovers, develops, and commercializes small-molecule drugs and gene therapies for rare genetic disorders, serving patients with phenylketonuria (PKU), AADC deficiency, Duchenne muscular dystrophy (DMD), Friedreich's ataxia, and Huntington's disease. Its commercial portfolio includes Sephience (oral sepiapterin for PKU, FDA-approved July 2025), Kebilidi (the first FDA-approved AAV gene therapy delivered directly into the brain, for AADC deficiency), Translarna (ataluren for nonsense mutation DMD, approved in Europe), and Emflaza (deflazacort for DMD). Pipeline assets include votoplam (PTC518, partnered with Novartis for Huntington's disease, currently in Phase 3) and vatiquinone (Friedreich's ataxia, pending FDA resubmission following a Complete Response Letter).

PTC operates two proprietary scientific platforms: Splicing (modulating pre-mRNA splicing to control protein production) and Inflammation/Ferroptosis (targeting oxidative stress and inflammation pathways). These platforms have produced multiple first-in-class therapies and generated license revenue (Evrysdi royalties sold to Royalty Pharma in December 2025 for $240 million plus milestones). The company monetizes through direct specialty drug sales across 50+ countries, supplemented by royalty and collaboration revenue. Q1 2026 revenue reached $273 million (with Sephience contributing $124.6 million), and management has guided 2026 total revenue of $1.08–1.18 billion. As of December 2025, PTC reported a cash position of $1.95 billion.

Name

PTC Therapeutics

Legal name

PTC Therapeutics, Inc.

Website

https://ptcbio.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

PTC Therapeutics is a global biopharmaceutical company that discovers, develops, and commercializes small-molecule drugs and gene therapies for rare genetic disorders including PKU, AADC deficiency, DMD, Friedreich's ataxia, and Huntington's disease, serving patients and healthcare providers across 50+ countries.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — Rare Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

akta.pro secondary industries

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

Keywords

• Rare disease therapeutics
• Biopharmaceutical medicines
• Gene therapy products
• Splicing modifier drugs
• Orphan drug development

Headquarters

HQ city

South Plainfield

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Product Sales: Commercial sales of approved drugs including Sephience (PKU), Emflaza (DMD), Translarna (nmDMD - Europe only), and Kebilidi (AADC deficiency)
2. Royalty Revenue: Royalties from Evrysdi (sold remaining royalties to Royalty Pharma for $240M upfront plus up to $60M milestones in December 2025)
3. Collaboration Revenue: Milestone payments and royalties from partnerships including Novartis for Huntington's disease program (received $1B upfront plus up to $1.9B in milestones)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

PTC Therapeutics is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated small-molecule drugs and gene therapies for children and adults with rare genetic disorders of high unmet need. Its commercial portfolio includes Sephience for phenylketonuria, Kebilidi (the first brain-delivered AAV gene therapy) for AADC deficiency, Emflaza for Duchenne muscular dystrophy, and Translarna (Europe only) for nonsense mutation DMD, supported by a pipeline built on proprietary Splicing and Inflammation/Ferroptosis platforms.

Product overview

PTC Therapeutics is a global biopharmaceutical company focused on rare diseases with both commercialized products and a clinical-stage pipeline. The commercial portfolio includes Sephience (oral PKU therapy, FDA-approved July 2025), Kebilidi (AADC deficiency gene therapy, FDA-approved November 2024), Translarna (DMD protein restoration therapy, EU-approved), and Emflaza (DMD corticosteroid). Revenue historically derived from DMD franchise (Translarna, Emflaza) and Evrysdi royalties (sold to Royalty Pharma), now transitioning to Sephience as primary growth driver. The clinical pipeline includes Votoplam for Huntington's disease (Phase 3, partnered with Novartis) and Vatiquinone for Friedreich's ataxia (pending FDA resubmission). PTC operates two scientific platforms: Splicing (modulating pre-mRNA splicing to control protein production) and Inflammation/Ferroptosis (targeting oxidative stress and inflammation pathways).

Differentiator

Problem solved

Functional benefit

Brands

• Sephience: Oral therapy for phenylketonuria (PKU) - approved in US (July 2025), EU, and Japan
• Upstaza/Kebilidi
• Translarna
• Emflaza
• PTC Cares
• Insightful Moments

Products and services

• Sephience (sepiapterin) Oral small-molecule therapy for phenylketonuria (PKU), approved across the U.S., EU, Japan, and Canada for patients of all ages and disease severity levels.
• Kebilidi / Upstaza (eladocagene exuparvovec-tneq) Adeno-associated virus (AAV) gene therapy delivered via intraparenchymal infusion into the putamen for AADC deficiency, the first FDA-approved gene therapy infused directly into the brain.
• Translarna (ataluren) Protein restoration therapy for nonsense mutation Duchenne muscular dystrophy (nmDMD), approved in Europe. PTC withdrew its FDA application after the FDA indicated the data were unlikely to meet effectiveness threshold, and the European authorization non-renewal was adopted.
• Emflaza (deflazacort) Corticosteroid treatment for Duchenne muscular dystrophy, part of PTC's legacy DMD franchise and now facing generic competition.
• Votoplam (PTC518) Investigational daily oral HTT-lowering pill for Huntington's disease, partnered with Novartis. Positive 24-month PIVOT-HD data showed 52% slowing of disease progression at the 10 mg dose, with Phase 3 INVEST-HD underway.
• Vatiquinone Investigational treatment for Friedreich's ataxia. PTC received a Complete Response Letter from the FDA in August 2025, with the FDA indicating an additional study will be required before resubmission.

Quantifiable outcome

• Sephience achieved $124.6M Q1 2026 sales, up 36% sequentially
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• NovartiscoreStrategic or Co-development Partner · 1 December 2024Exclusive global license and collaboration agreement for PTC518 (votoplam) Huntington's disease program. PTC received $1.0 billion upfront and up to $1.9 billion in milestone payments, with Novartis assuming development, manufacturing, and commercial responsibilities after trial completion. PTC retains 40% share of U.S. profits and double-digit tiered royalties on international sales. Novartis initiated global Phase 3 INVEST-HD trial following positive PIVOT-HD data.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Sarepta Therapeutics: Sarepta is the closest DMD competitor, with approved gene therapies (Elevidys) overlapping PTC's DMD franchise (Emflaza/Translarna). Both companies operate in the rare neuromuscular disease space with high-priced, modality-differentiated therapies targeting small populations.
• Ultragenyx Pharmaceutical: Ultragenyx is a rare-disease biotech with direct PKU competition (Crysvita-adjacent metabolic positioning and ongoing work in metabolic rare disease) and a parallel commercial-stage portfolio across multiple rare genetic disorders. Comparable in therapeutic area focus and global launch model.
• Catalyst Pharmaceuticals: Catalyst is a rare-disease commercial biopharma with a similar operating model: small patient populations, high-priced orphan drugs, and global launch infrastructure. Comparable in commercial economics and go-to-market motion.
• Travere Therapeutics: Travere is a smaller rare-disease biopharma with overlap in genetic metabolic and neurological indications. Comparable in commercial-stage rare disease focus and reliance on a small number of high-priced orphan drugs for growth.
• BioMarin Pharmaceutical: BioMarin is the most directly comparable peer — both are commercial-stage rare-disease biopharmas with overlapping PKU franchises (Palynziq/Kuvan vs. Sephience) and parallel strategies in small patient populations with high unmet need. BioMarin also competes in adjacent genetic disease areas like AADC, DMD (indirectly), and enzyme replacement.

Others

• Genentech (Roche): Roche/Genentech is the originator and commercializer of Evrysdi, originally licensed from PTC's splicing platform. Comparable as the partner whose commercialization drove PTC's Evrysdi royalty stream (now sold to Royalty Pharma). Indirectly aligned through shared scientific origin.
• Novartis: Novartis is PTC's strategic partner on votoplam for Huntington's disease ($1B upfront + up to $1.9B in milestones). Comparable as a large biopharma partner assuming late-stage development and commercialization of PTC-discovered assets, providing a benchmark for partner economics and pipeline value.

Broad incumbents

• Vertex Pharmaceuticals: Vertex is a larger commercial-stage rare-disease biopharma with a focused portfolio in cystic fibrosis, sickle cell, and pain, and emerging rare disease pipeline. Comparable in operating model (orphan-drug commercial infrastructure, modality breadth, and rare-disease pricing dynamics) though larger and more diversified.
• Ionis Pharmaceuticals: Ionis is an antisense-based rare-disease biopharma with a similar platform-to-product model and a marketed rare-disease portfolio. Comparable in scientific platform leverage and orphan drug commercial economics.
• Alnylam Pharmaceuticals: Alnylam is a larger rare-disease biopharma built on a single differentiated platform (RNAi) analogous to PTC's Splicing/Inflammation-Ferroptosis platforms. Comparable in modality-driven platform leverage and rare-disease commercial focus, though larger and more diversified.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PTCBio
• Facebookfacebook.com/106075039423774
• Instagraminstagram.com/ptctherapeutics
• LinkedInlinkedin.com/company/ptc-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds16 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PTC Therapeutics